Navigation Links
Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Date:3/13/2008

http://www.nilethera.com.

Contact:

Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.

510-281-7700

info@nilethera.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section of our Prospectus filed pursuant to Rule 424(b)(3) of the Securities Act of 1933, as amended, with the Securities and Exchange Commission on November 15, 2007. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

STATEMENTS OF OPERATIONS

Three Months Ended Twelve Months Ended

December 31, 2007 December 31, 2007

Grant income -
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
2. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
6. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
7. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
8. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... ,, SEATTLE,Nov.24/PRNewswire/--BlueMarbleEn...ublicDevelopmentAuthority(OPDA)wererecentlyawarded...alizationBoard(CERB)inaprivate/publicpartnershipto...ineryinLincolnCounty,WA. ,, "Thisinvestmentwill...dbringover70greenjobstoLincolnCounty,"saidBlueMarb...
(Date:11/24/2009)... ,, TSXVENTURE:HTL , TORONTO,Nov.24/PRN...ormerlyCalottoCapitalInc.,aleadingproviderofadvanc...andfertilityclinicmarkets,todayreportedoperational...r30,2009. , ,Q32009Highlights,-Revenuewas$1.46mi...marginwas66.3percentcomparedwith66.1percentinQ3,20...
(Date:11/24/2009)... ,, REDWOODCITY,Calif.,Nov.24/PRNewswire-Fir...ouncedthatRandyScott,GenomicHealth,sExecutiveChair...reConferenceinNewYorkCityonTuesday,December1,2009a...archivedwebcastofthepresentation,visittheInvestorR...nvestor.genomichealth.com .Pleaseconnecttothewebsi...
(Date:11/24/2009)... , Chemical Abstracts Ser...ion, reports that China,s patent office is now the...ications in chemistry. China trailed Japan,s paten...tion (WIPO), and the United States Patent and Trad...assed the USPTO in 2005, WIPO in 2006, and exceede...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Genomic Health to Present at Piper Jaffray Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
...ylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will We...y, May 30, 2008 at 11:00 a.m. PT from the company,...ng the Annual Meeting, Daniel M.,Bradbury, Preside...ticals,will be providing a corporate overview., T...ding will be made,available following the event. T...
...wswire/ - ImmunoVaccine Technologies Inc. (IVT), a...mila Philip for being,recognized as one of Pennsyl...ip, Co-Founder and President of Immunotope Inc., r...rd G. Rendell., "Ramila is a champion in the biot...ry for ovarian and breast cancer is inspiring," co...
...wswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,...it has been granted,Canadian Patent 2,360,833 enti...ferative Disorders." The claims describe the use o...mediated proliferative disorders., "This patent p...ion for,the use of reovirus compositions for cance...
Other Biology Technology:ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PA's Best 50 Women in Business 2Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent 2
(Date:11/23/2009)...AMES, Iowa - The only swine vaccine available for ...herd infected with the virus. The vaccination mark...herd diagnosed with the pandemic flu., Iowa Stat...ience, developed the vaccine this summer and has b...n Iowa, Kansas and Illinois for several weeks., ...
(Date:11/23/2009)...DISON, WI, November 16, 2009 -- A USDOE and USDA s...and, idle cropland, and cropland pasture could be ...erennial grasses, such as switchgrass, from which ...edstock. Economically viable production of a peren...tities of biomass are removed annually is expected...
(Date:11/23/2009)...DURHAM, N.H. University of New Hampshire microbio... $498,115 to advance understanding of the actinorh...l to enrich nutrient-poor and contaminated soils. ...USDA) awarded Tisa, a professor of molecular, cell...the symbiotic relationship between the bacteria Fr...
Breaking Biology News(10 mins):Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2UNH prof. receives nearly $500,000 to research environmentally significant plants 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnersh 14747 1Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnersh 14747 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnersh 14747 3Top 10 Ways to Prevent or Delay Alzheimer 26apos 3Bs 60811 1Top 10 Ways to Prevent or Delay Alzheimer 26apos 3Bs 60811 2Federal Judge Rejects Tobacco Companies Effort to Block Key Provisions of New Tobacco Regulation Law 60808 1Federal Judge Rejects Tobacco Companies Effort to Block Key Provisions of New Tobacco Regulation Law 60808 2
...ool of Tropical Medicine (LSTM) and the University...ject grant to begin the development of new drugs t...llcome Trust, aims to develop new antimalarial dru...e in the respiratory chain of Plasmodium falcipar...me within the parasite is not found in humans, the...
...e University of Vermont Cardiovascular Research In...ased expression in the heart of plasminogen activa...results, which appear in the March 2009 issue of ...1 overexpression, known to accompany insulin resis...g to the high incidence of heart failure after myo...
...3 Military, homeland security, law enforcement an...nited States are being encouraged to attend the 20...VII) in northern Virginia this May 19-21. , , Nea...nty Regional Airport, just south of Marine Corps B...ives survivability demonstrations will be at range...
Other Biology News:LSTM and UoL secure £1.4m ($2m) to develop new 'magic bullet' antimalarial drug 2Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes 2Demonstration Targets Terrorism 2
...Beacon Designer designs oligos for SYBR Green, Taq...on, NASBA and FRET assays. Highly specific primers...y automatically interpreting BLAST search results....e secondary structures identified by connecting to...
Agar (BACTERIOLOGICAL GRADE) from GE Healthcare, formerly Amersham Biosciences
Silencer Validated siRNA 5 nmol from Ambion
SPoT-Light EGFR Probe from Invitrogen
Biology Products: